| A comparison of allografting with autografting for newly diagnosed myeloma B Bruno, M Rotta, F Patriarca, N Mordini, B Allione, F Carnevale-Schianca, ... New England Journal of Medicine 356 (11), 1110-1120, 2007 | 659 | 2007 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 550 | 2020 |
| Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25–into CD25+ T regulatory cells A Curti, S Pandolfi, B Valzasina, M Aluigi, A Isidori, E Ferri, V Salvestrini, ... Blood 109 (7), 2871-2877, 2007 | 462 | 2007 |
| Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial A Palumbo, S Bringhen, MT Petrucci, P Musto, F Rossini, M Nunzi, ... Blood 104 (10), 3052-3057, 2004 | 392 | 2004 |
| CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib R Piva, B Ruggeri, M Williams, G Costa, I Tamagno, D Ferrero, V Giai, ... Blood, The Journal of the American Society of Hematology 111 (5), 2765-2775, 2008 | 331 | 2008 |
| Zoledronic acid repolarizes tumour‐associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway M Coscia, E Quaglino, M Iezzi, C Curcio, F Pantaleoni, C Riganti, I Holen, ... Journal of cellular and molecular medicine 14 (12), 2803-2815, 2010 | 317 | 2010 |
| Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia D Rossi, L Terzi-di-Bergamo, L De Paoli, M Cerri, G Ghilardi, A Chiarenza, ... Blood, The Journal of the American Society of Hematology 126 (16), 1921-1924, 2015 | 266 | 2015 |
| Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease R Foa, M Massaia, S Cardona, AG Tos, A Bianchi, C Attisano, A Guarini, ... Blood 76 (2), 393-400, 1990 | 243 | 1990 |
| Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy M Massaia, P Borrione, S Battaglio, S Mariani, E Beggiato, P Napoli, ... Blood, The Journal of the American Society of Hematology 94 (2), 673-683, 1999 | 190 | 1999 |
| Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy V Squadrone, M Massaia, B Bruno, F Marmont, M Falda, C Bagna, ... Intensive care medicine 36 (10), 1666-1674, 2010 | 185 | 2010 |
| Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol‐anchored lymphocyte differentiation antigen ecto‐5′‐nucleotidase (CD73). LF Thomson, JM Ruedi, A Glass, G Moldenhauer, P Moller, MG Low, ... Tissue Antigens 35 (1), 9-19, 1990 | 178 | 1990 |
| Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma S Mariani, M Muraro, F Pantaleoni, F Fiore, B Nuschak, S Peola, ... Leukemia 19 (4), 664-670, 2005 | 162 | 2005 |
| Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma L Giaccone, B Storer, F Patriarca, M Rotta, R Sorasio, B Allione, ... Blood 117 (24), 6721, 2011 | 148 | 2011 |
| Chlorambucil plus rituximab with or without maintenance rituximab as first‐line treatment for elderly chronic lymphocytic leukemia patients R Foà, I Del Giudice, A Cuneo, G Del Poeta, S Ciolli, F Di Raimondo, ... American journal of hematology 89 (5), 480-486, 2014 | 143 | 2014 |
| Antitumor vaccination: where we stand M Bocchia, V Bronte, MP Colombo, A De Vincentiis, M Di Nicola, G Forni, ... Haematologica 85 (11), 1172-1206, 2000 | 133 | 2000 |
| Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase A Curti, M Aluigi, S Pandolfi, E Ferri, A Isidori, V Salvestrini, I Durelli, ... Leukemia 21 (2), 353-355, 2007 | 131 | 2007 |
| Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia D Rossi, C Lobetti Bodoni, E Genuardi, L Monitillo, D Drandi, M Cerri, ... Leukemia 23 (6), 1062-1072, 2009 | 117 | 2009 |
| Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid F Fiore, B Castella, B Nuschak, R Bertieri, S Mariani, B Bruno, ... Blood, The Journal of the American Society of Hematology 110 (3), 921-927, 2007 | 115 | 2007 |
| Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study A Palumbo, S Bringhen, B Bruno, AP Falcone, AM Liberati, M Grasso, ... Blood, The Journal of the American Society of Hematology 115 (10), 1873-1879, 2010 | 113 | 2010 |
| Distribution of terminal deoxynucleotidyl transferase and purine degradative and synthetic enzymes in subpopulations of human thymocytes DD Ma, TA Sylwestrowicz, S Granger, M Massaia, R Franks, G Janossy, ... The Journal of Immunology 129 (4), 1430, 1982 | 112 | 1982 |
Antonio PalumboUniversità di Torino; Torino Italy在 unito.it 的电子邮件经过验证
